Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061775 · ClinicalTrials.gov registry record · Phase 1
Effects of Exenatide on Hypothalamic Obesity
A Phase 1 study of Hypothalamic Obesity, sponsored by Children's Hospitals and Clinics of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT01061775: Completed Phase 1 study of Hypothalamic Obesity, sponsored by Children's Hospitals and Clinics of Minnesota.
NCT01061775 is a Phase 1 study of Hypothalamic Obesity that has completed, run by Children's Hospitals and Clinics of Minnesota. The registered enrollment target is 19 participants, below the 74-participant average among 5 other Hypothalamic Obesity trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01061775, a Phase 1 study of Hypothalamic Obesity, has completed, sponsored by Children's Hospitals and Clinics of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.
Primary Outcome
BMI was collected at baseline and 24 weeks
Conditions Studied
Interventions
- DRUG Exenatide
Study Locations (2)
California
- Children's Hospital of Orange County - Orange
Minnesota
- Children's Hospitals & Clincis of Minnesota - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-01 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 1 |
What the finished NCT01061775 record still lists
NCT01061775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 74-participant average among 5 other Hypothalamic Obesity trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Hypothalamic Obesity appearing as the primary indexed condition, and to 1 intervention - of which Exenatide is the first listed.
NCT01061775 reports a single indexed study location in California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01061775 about?
NCT01061775 is a clinical study titled "Effects of Exenatide on Hypothalamic Obesity". The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic o...
What is the current status of trial NCT01061775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2010-01. Estimated completion is 2019-03-15.
What conditions does trial NCT01061775 study?
This clinical trial studies the following conditions: Hypothalamic Obesity.
What interventions are being tested in trial NCT01061775?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT01061775?
This trial is sponsored by Children's Hospitals and Clinics of Minnesota, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01061775 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypothalamic Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
RECRUITING · Phase 1
-
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
RECRUITING · Phase 3
-
Tirzepatide in PWS, HO and GNSO
RECRUITING · Phase 4
-
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
RECRUITING · Phase 2
-
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia